全文获取类型
收费全文 | 80436篇 |
免费 | 5507篇 |
国内免费 | 695篇 |
专业分类
耳鼻咽喉 | 1256篇 |
儿科学 | 1664篇 |
妇产科学 | 1888篇 |
基础医学 | 11252篇 |
口腔科学 | 1979篇 |
临床医学 | 8027篇 |
内科学 | 17552篇 |
皮肤病学 | 1740篇 |
神经病学 | 7050篇 |
特种医学 | 3343篇 |
外科学 | 10485篇 |
综合类 | 836篇 |
一般理论 | 59篇 |
预防医学 | 4768篇 |
眼科学 | 1707篇 |
药学 | 6135篇 |
1篇 | |
中国医学 | 393篇 |
肿瘤学 | 6503篇 |
出版年
2023年 | 471篇 |
2022年 | 334篇 |
2021年 | 1822篇 |
2020年 | 1240篇 |
2019年 | 1800篇 |
2018年 | 2140篇 |
2017年 | 1751篇 |
2016年 | 2163篇 |
2015年 | 2548篇 |
2014年 | 3196篇 |
2013年 | 4185篇 |
2012年 | 6237篇 |
2011年 | 6499篇 |
2010年 | 3884篇 |
2009年 | 3458篇 |
2008年 | 5135篇 |
2007年 | 5344篇 |
2006年 | 4789篇 |
2005年 | 4782篇 |
2004年 | 4276篇 |
2003年 | 4036篇 |
2002年 | 3672篇 |
2001年 | 1155篇 |
2000年 | 1004篇 |
1999年 | 1048篇 |
1998年 | 677篇 |
1997年 | 576篇 |
1996年 | 505篇 |
1995年 | 511篇 |
1994年 | 450篇 |
1993年 | 402篇 |
1992年 | 532篇 |
1991年 | 456篇 |
1990年 | 470篇 |
1989年 | 474篇 |
1988年 | 438篇 |
1987年 | 367篇 |
1986年 | 349篇 |
1985年 | 370篇 |
1984年 | 319篇 |
1983年 | 274篇 |
1982年 | 268篇 |
1981年 | 228篇 |
1980年 | 206篇 |
1979年 | 234篇 |
1978年 | 201篇 |
1977年 | 195篇 |
1976年 | 137篇 |
1975年 | 165篇 |
1974年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 241 毫秒
1.
Jos B. Poell Leon J. Wils Arjen Brink Ralf Dietrich Christine Krieg Eunike Velleuer Ilkay Evren Elisabeth R. Brouns Jan G. de Visscher Elisabeth Bloemena Bauke Ylstra Ruud H. Brakenhoff 《International journal of cancer. Journal international du cancer》2023,152(2):227-238
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient. 相似文献
2.
3.
4.
5.
Kari Hemminki Kristina Sundquist Jan Sundquist Asta Försti Vaclav Liska Akseli Hemminki Xinjun Li 《International journal of cancer. Journal international du cancer》2023,152(6):1107-1114
Many environmental risk factors for hepatobiliary cancers are known but whether they are associated with specific cancer types is unclear. We present here a novel approach of assessing standardized incidence ratios (SIRs) of previously diagnosed comorbidities for hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cholangiocarcinoma (CCA) and ampullary cancer. The 13 comorbidities included alcohol and nonalcohol related liver disease, chronic obstructive pulmonary disease, gallstone disease, viral and other kinds of hepatitis, infection of bile ducts, hepatic and other autoimmune diseases, obesity and diabetes. Patients were identified from the Swedish Inpatient Register from 1987 to 2018, and their cancers were followed from 1997 onwards. SIRs for HCC were 80 to 100 in men and women diagnosed with hepatitis C virus and they were also >10 in patients diagnosed with hepatitis B virus, other kind of hepatitis, hepatic autoimmune disease and nonalcohol related liver disease. Many of these risks, as well as alcohol related liver disease, were either specific to HCC or were shared with intrahepatic CCA. For GBC, CCA and ampullary cancer infection of bile ducts was the main risk factor. Gallstone disease, nonhepatic autoimmune diseases and diabetes were associated with all hepatobiliary cancers. The limitations of the study include inability to cover some rare risk factors and limited follow-up time. Many of the considered comorbidities are characterized by chronic inflammation and/or overt immune disturbance in autoimmune diseases. The results suggest that local chronic inflammation and a related immune disturbance is the carcinogenic trigger for all these cancers. 相似文献
6.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83
7.
Helmer Philipp Schlesinger Tobias Hottenrott Sebastian Papsdorf Michael Wöckel Achim Diessner Joachim Stumpner Jan Sitter Magdalena Skazel Tobias Wurmb Thomas Härtel Christoph Hofer Stefan Alkatout Ibrahim Girard Thierry Meybohm Patrick Kranke Peter 《Der Anaesthesist》2022,71(3):171-180
Die Anaesthesiologie - Die Implementierung eines Patient Blood Management (PBM) wird zunehmender Standard in der operativen Medizin. Seit einiger Zeit gilt das Interesse auch den vulnerablen... 相似文献
8.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
9.
Josupeit Jan Dadaczynski Kevin Quilling Eike 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(7-8):829-835
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Die Schule ist einer der wichtigsten Orte, an dem die Förderung der Gesundheit von Kindern und Jugendlichen ansetzen kann,... 相似文献
10.
Emilie M.J. van Brummelen Sanne Huijberts Carla van Herpen Ingrid Desar Frans Opdam Robin van Geel Serena Marchetti Neeltje Steeghs Kim Monkhorst Bas Thijssen Hilde Rosing Alwin Huitema Jos Beijnen Rene Bernards Jan Schellens 《The oncologist》2021,26(4):290-e545
Lessons Learned
- Afatinib and selumetinib can be combined in continuous and intermittent dosing schedules, albeit at lower doses than approved for monotherapy.
- Maximum tolerated dose for continuous and intermittent schedules is afatinib 20 mg once daily and selumetinib 25 mg b.i.d.
- Because the anticancer activity was limited, further development of this combination is not recommended until better biomarkers for response and resistance are defined.